Cargando…

Choroidal evaluation in patients under alpha-lytic therapy

PURPOSE: To detect any choroidal thickness (CT) change in patients after alpha-lytic drugs withdrawal that could help in the cataract surgery timing decision. METHODS: Twenty-five eyes of 25 patients (mean age: 76 ± 7 years) under alpha-lytic therapy, and 25 eyes of 25 control subjects (CS) (mean ag...

Descripción completa

Detalles Bibliográficos
Autores principales: De Bernardo, Maddalena, Altieri, Vincenzo, Coppola, Alessia, Gioia, Marco, Rosa, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677155/
https://www.ncbi.nlm.nih.gov/pubmed/32875394
http://dx.doi.org/10.1007/s00417-020-04907-1
_version_ 1783611920111108096
author De Bernardo, Maddalena
Altieri, Vincenzo
Coppola, Alessia
Gioia, Marco
Rosa, Nicola
author_facet De Bernardo, Maddalena
Altieri, Vincenzo
Coppola, Alessia
Gioia, Marco
Rosa, Nicola
author_sort De Bernardo, Maddalena
collection PubMed
description PURPOSE: To detect any choroidal thickness (CT) change in patients after alpha-lytic drugs withdrawal that could help in the cataract surgery timing decision. METHODS: Twenty-five eyes of 25 patients (mean age: 76 ± 7 years) under alpha-lytic therapy, and 25 eyes of 25 control subjects (CS) (mean age: 75 ± 7 years) without alpha-lytic therapy, both scheduled for cataract surgery in the fellow eye, were included in this observational, prospective, non-randomized study. All patients underwent EDI-OCT during the first preoperative visit and approximately 1 month (range 28–31 days) after alpha-lytic withdrawal. In the CS group, the OCT during preoperative visit and approximately 1 month after (range 28–31 days) the first examination was performed. Data normality with Kolmogorov-Smirnov test was checked and statistical evaluation with the Wilcoxon-signed rank test was performed. RESULTS: The mean subfoveal CT was 224 ± 79.7 μm during therapy and 217 ± 70.4 μm after withdrawal; 1.5 mm nasally from the fovea CT was 198 ± 83.8 μm and 194 ± 82.8 μm, respectively; and 1.5 mm temporally from the fovea CT was 217 ± 55.9 μm and 205 ± 54.4 μm, respectively. A statistically significant reduction (p < 0.05) in all the 3 measured CT points was found. In the CS no significant changes were detected (p > 0.05). CONCLUSION: No severe floppy iris syndrome was detected at the time of surgery. In these patients, CT decrease could be an important sign for cataract surgery timing decision.
format Online
Article
Text
id pubmed-7677155
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-76771552020-11-30 Choroidal evaluation in patients under alpha-lytic therapy De Bernardo, Maddalena Altieri, Vincenzo Coppola, Alessia Gioia, Marco Rosa, Nicola Graefes Arch Clin Exp Ophthalmol Cataract PURPOSE: To detect any choroidal thickness (CT) change in patients after alpha-lytic drugs withdrawal that could help in the cataract surgery timing decision. METHODS: Twenty-five eyes of 25 patients (mean age: 76 ± 7 years) under alpha-lytic therapy, and 25 eyes of 25 control subjects (CS) (mean age: 75 ± 7 years) without alpha-lytic therapy, both scheduled for cataract surgery in the fellow eye, were included in this observational, prospective, non-randomized study. All patients underwent EDI-OCT during the first preoperative visit and approximately 1 month (range 28–31 days) after alpha-lytic withdrawal. In the CS group, the OCT during preoperative visit and approximately 1 month after (range 28–31 days) the first examination was performed. Data normality with Kolmogorov-Smirnov test was checked and statistical evaluation with the Wilcoxon-signed rank test was performed. RESULTS: The mean subfoveal CT was 224 ± 79.7 μm during therapy and 217 ± 70.4 μm after withdrawal; 1.5 mm nasally from the fovea CT was 198 ± 83.8 μm and 194 ± 82.8 μm, respectively; and 1.5 mm temporally from the fovea CT was 217 ± 55.9 μm and 205 ± 54.4 μm, respectively. A statistically significant reduction (p < 0.05) in all the 3 measured CT points was found. In the CS no significant changes were detected (p > 0.05). CONCLUSION: No severe floppy iris syndrome was detected at the time of surgery. In these patients, CT decrease could be an important sign for cataract surgery timing decision. Springer Berlin Heidelberg 2020-09-02 2020 /pmc/articles/PMC7677155/ /pubmed/32875394 http://dx.doi.org/10.1007/s00417-020-04907-1 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Cataract
De Bernardo, Maddalena
Altieri, Vincenzo
Coppola, Alessia
Gioia, Marco
Rosa, Nicola
Choroidal evaluation in patients under alpha-lytic therapy
title Choroidal evaluation in patients under alpha-lytic therapy
title_full Choroidal evaluation in patients under alpha-lytic therapy
title_fullStr Choroidal evaluation in patients under alpha-lytic therapy
title_full_unstemmed Choroidal evaluation in patients under alpha-lytic therapy
title_short Choroidal evaluation in patients under alpha-lytic therapy
title_sort choroidal evaluation in patients under alpha-lytic therapy
topic Cataract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677155/
https://www.ncbi.nlm.nih.gov/pubmed/32875394
http://dx.doi.org/10.1007/s00417-020-04907-1
work_keys_str_mv AT debernardomaddalena choroidalevaluationinpatientsunderalphalytictherapy
AT altierivincenzo choroidalevaluationinpatientsunderalphalytictherapy
AT coppolaalessia choroidalevaluationinpatientsunderalphalytictherapy
AT gioiamarco choroidalevaluationinpatientsunderalphalytictherapy
AT rosanicola choroidalevaluationinpatientsunderalphalytictherapy